Core Insights - The top three companies by Hong Kong Stock Connect holding ratios are China Telecom (00728) at 72.44%, Green Power Environmental (01330) at 69.47%, and Da Zhong Public Utilities (01635) at 69.41% [1][2] - Alibaba-W (09988), Tracker Fund of Hong Kong (02800), and Xiaomi Group-W (01810) saw the largest increases in holding amounts over the last five trading days, with increases of +6.391 billion, +5.358 billion, and +2.533 billion respectively [1][2] - WuXi Biologics (02269), China Mobile (00941), and Crystal International (02228) experienced the largest decreases in holding amounts, with reductions of -612 million, -485 million, and -473 million respectively [1][3] Hong Kong Stock Connect Holding Ratios - China Telecom (00728) holds 10.054 billion shares, representing 72.44% of its total [2] - Green Power Environmental (01330) holds 281 million shares, representing 69.47% of its total [2] - Da Zhong Public Utilities (01635) holds 370 million shares, representing 69.41% of its total [2] Recent Increases in Holdings - Alibaba-W (09988) saw an increase of +6.391 billion in holding amount, with a change of +41.368 million shares [2] - Tracker Fund of Hong Kong (02800) increased by +5.358 billion, with a change of +207.532 million shares [2] - Xiaomi Group-W (01810) increased by +2.533 billion, with a change of +65.508 million shares [2] Recent Decreases in Holdings - WuXi Biologics (02269) decreased by -612 million in holding amount, with a change of -19.247 million shares [3] - China Mobile (00941) decreased by -485 million, with a change of -5.542 million shares [3] - Crystal International (02228) decreased by -473 million, with a change of -46.770 million shares [3]

Group 1 - Morgan Stanley's research report indicates that WuXi AppTec's valuation levels are attractive amid a stable fundamental backdrop, with a particular focus on WuXi Biologics [1] - The report highlights that WuXi Biologics has raised its earnings guidance and is undergoing significant capacity expansion, with high participation in the next-generation GLP-1 sector [1] - The firm has upgraded earnings forecasts for WuXi Biologics for 2025 to 2027 by 6% to 13%, and for WuXi AppTec by 3% to 4%, designating WuXi AppTec as a top pick [1] Group 2 - The compound annual growth rates for the three companies from 2024 to 2027 are projected at 24%, 23%, and 37% respectively [1] - Other major banks, including Oriental Securities and Goldman Sachs, have also maintained positive ratings on WuXi AppTec and WuXi Biologics, citing strong performance and robust customer demand [2] - Goldman Sachs set a target price of HKD 63.3 for WuXi AppTec, reflecting confidence in the company's order momentum and customer demand [2]

Group 1 - CRO concept stocks have collectively rebounded, indicating a positive trend in the sector [1] - Tigermed (03347.HK) increased by 9.19%, reaching HKD 39.92 [1] - WuXi AppTec (02359.HK) rose by 4.43%, trading at HKD 106 [1] - Kanglong Chemical (03759.HK) saw a 4.15% increase, priced at HKD 21.58 [1] - WuXi Biologics (02269.HK) experienced a 3.27% rise, with a price of HKD 31.56 [1]

Core Insights - The Hong Kong stock market indices saw significant gains in the afternoon, with the Hang Seng Index rising over 2%, the Hang Seng Tech Index increasing by 2.7%, and the Hang Seng China Enterprises Index up by 1.8% [1] Company Performance - Kuaishou (快手-W) experienced a rise of 6.56% with a year-to-date increase of 66.79%, and a total market capitalization of 294.57 billion [2] - NetEase (网易-S) increased by 6.26%, with a year-to-date gain of 61.57%, and a market cap of 688.29 billion [2] - Alibaba (阿里巴巴-W) rose by 5.42%, showing a year-to-date increase of 93.41%, with a total market value of 2.97 trillion [2] - WuXi AppTec (药明康德) saw a 4.14% increase, with a year-to-date rise of 93.30%, and a market capitalization of 315.38 billion [2] - Baidu (百度集团-SW) increased by 4.10%, with a year-to-date gain of 35.07%, and a market cap of 307.19 billion [2] - Hansoh Pharmaceutical (翰森制药) rose by 4.03%, with a remarkable year-to-date increase of 134.85%, and a market capitalization of 240.51 billion [2] - Zhongsheng Holdings (中升控股) increased by 3.58%, but has a year-to-date decline of 12.81%, with a market cap of 27.41 billion [2] - China Overseas Development (中国海外发展) rose by 3.37%, with a year-to-date increase of 19.16%, and a market cap of 154.54 billion [2] - Longfor Group (龙湖集团) increased by 3.54%, with a year-to-date rise of 6.20%, and a market cap of 72.18 billion [2] - BYD (比亚迪股份) rose by 3.34%, with a year-to-date increase of 9.64%, and a market cap of 873.88 billion [2] - WuXi Biologics (药明生物) increased by 3.34%, with a year-to-date rise of 79.84%, and a market cap of 129.71 billion [2] - Midea Group (美的集团) rose by 2.92%, with a year-to-date increase of 26.14%, and a market cap of 690.12 billion [2] - Meituan (美团-W) increased by 2.88%, but has a year-to-date decline of 35.20%, with a market cap of 600.76 billion [2] - Alibaba Health (阿里健康) rose by 2.87%, with a year-to-date increase of 72.59%, and a market cap of 92.68 billion [2]

摩根士丹利发布研报称，医疗股自9月中旬起被持续抛售，投资者正在获利了结，并等待明年业绩发展 的讯号。该行指出，当中药明系在基本面持续稳健的背景下，估值水平更具吸引力。大摩最看好药明康 德，该公司不仅上调业绩指引，更进行大规模产能扩张，且在下一代GLP-1领域参与度高。综合而言， 药明康德、药明生物及药明合联2024至27年的盈利复合年增长率分别为24%、23%及37%。 招银国际认为，资本市场融资活动恢复，创新药出海交易规模扩张，国内创新药研发需求回暖，加上美 国进入降息周期，CXO企业下半年业绩表现有望复苏，招银国际预期已授权的创新药管线在海外的临 床发展可成为创新药板块最重要催化剂。 智通财经APP获悉，CRO概念股集体回暖。截至发稿，泰格医药(03347)涨9.19%，报39.92港元；药明康 德(02359)涨4.43%，报106港元；康龙化成(03759)涨4.15%，报21.58港元；药明生物(02269)涨3.27%，报 31.56港元。 ...

招银国际认为，资本市场融资活动恢复，创新药出海交易规模扩张，国内创新药研发需求回暖，加上美 国进入降息周期，CXO企业下半年业绩表现有望复苏，招银国际预期已授权的创新药管线在海外的临 床发展可成为创新药板块最重要催化剂。 摩根士丹利发布研报称，医疗股自9月中旬起被持续抛售，投资者正在获利了结，并等待明年业绩发展 的讯号。该行指出，当中药明系在基本面持续稳健的背景下，估值水平更具吸引力。大摩最看好药明康 德，该公司不仅上调业绩指引，更进行大规模产能扩张，且在下一代GLP-1领域参与度高。综合而言， 药明康德、药明生物及药明合联2024至27年的盈利复合年增长率分别为24%、23%及37%。 CRO概念股集体回暖。截至发稿，泰格医药（300347）(03347)涨9.19%，报39.92港元；药明康德 （603259）(02359)涨4.43%，报106港元；康龙化成（300759）(03759)涨4.15%，报21.58港元；药明生 物(02269)涨3.27%，报31.56港元。 ...

Summary of WuXi Biologics Conference Call Company Overview - **Company**: WuXi Biologics (2269.HK) - **Event**: APAC Healthcare Corporate Day 2025 - **Date**: November 20, 2025 Key Industry Insights - **New Order Momentum**: Management indicated that new order momentum remains robust as the company heads into Q4 2025, with expectations for accelerated revenue and earnings growth in 2026 [2][3] - **R&D Projects**: A rebound in R&D projects was noted, driven by global funding recovery and increased PPQ scheduling. Bi-/multi-specific antibodies and ADCs are identified as key growth drivers, with respective project increases of +36.6% y/y to 168 projects and +34.7% y/y to 225 projects, together accounting for 71% of new projects as of 1H25 [3][2] Financial Performance and Projections - **Revenue Guidance**: Management plans to provide further clarity on revenue and project guidance at an industry conference in early 2026, with detailed updates expected during the full-year earnings release in March 2026 [2] - **Capex Plan**: The annual capital expenditure (capex) budget is projected to exceed RMB 5 billion through 2027, focusing on overseas expansion. Long-term capacity is targeted to reach 500kL, with 50% of this capacity located in China [4][7] Operational Efficiency - **Margin Management**: The margin dilution from the Singapore site is considered manageable due to favorable tax policies and operational efficiencies. Utilization rates at domestic sites have improved from 60% to 65% and are expected to continue rising [8][2] - **Project Updates**: A project at the Shijiazhuang site has received Breakthrough Therapy Designation (BTD) and is targeted for Biologics License Application (BLA) filing by year-end, which could significantly enhance utilization post-launch [8] Risks and Price Target - **Price Target**: The 12-month price target is set at HK$33.50, based on a forward P/E of 26x, indicating a potential upside of 4.9% from the current price of HK$31.92 [10] - **Risks**: Key risks include potential legislative impacts on US revenue, cooling of global biotech funding, and increasing competition from global players [9][10] Conclusion WuXi Biologics is positioned for growth with strong order momentum and strategic expansion plans. The focus on R&D and operational efficiency, alongside a robust capex plan, supports the company's outlook for 2026. However, investors should remain cautious of external risks that could impact performance.

智通财经APP获悉，根据2025年11月21日披露数据，中国电信（00728）、绿色动力环保（01330）、大 眾公用（01635）位居港股通持股比例前3位，分别为72.38%、69.48%、69.45%。此外，阿里巴巴－W （09988）、小米集团－Ｗ（01810）、盈富基金（02800）在最近有统计数据的5个交易日内，持股额增 幅最大，分别为+70.62亿元、+33.67亿元、+15.78亿元;药明生物（02269）、中国神华（01088）、中国 移动（00941）在最近有统计数据的5个交易日内，持股额减幅最大，分别为-6.43亿元、-3.93亿 元、-3.75亿元。 具体数据如下（交易所数据根据T+2日结算）： 1、港股通最新持股比例排行（前20名） | 公司名称 | 持股数量 | 最新持股比例 | | --- | --- | --- | | 中国电信(00728) | 100.45亿股 | 72.38% | | 绿色动力环保(01330) | 2.81亿股 | 69.48% | | 大眾公用(01635) | 3.71亿股 | 69.45% | | 昊天国际建投(01341) | 74.82亿股 | ...

Core Viewpoint - The CXO sector in the A-share market is experiencing significant growth, with 20 out of 29 listed companies reporting year-on-year revenue increases in the first three quarters, driven by internationalization and policy support for innovative drug companies [1][2]. Group 1: Industry Trends - Three major trends are emerging in the innovative drug sector: 1. Deepening internationalization 2.0, with an expected 103 license-out transactions and a record upfront payment of $8.45 billion by 2025, leading to valuation premiums for companies going abroad [2]. 2. Unprecedented policy support, including improved efficiency in medical insurance negotiations and the establishment of a commercial insurance directory for innovative drugs [2]. 3. Continuous technological breakthroughs, with advancements in ADC, IO dual antibodies, GLP-1 weight loss drugs, and small nucleic acid drugs [2]. Group 2: Market Outlook - The CXO industry adjustment is largely complete, with stable overseas demand and a rebound in domestic investment and financing, particularly for CDMO companies with strong international capabilities and leading clinical CROs [2]. - The recovery of the upstream industry chain is significant, with ample room for increasing domestic production rates, driven by smart and digital production alongside international expansion [2]. - The capital market's recovery in financing activities and the expansion of innovative drug transactions abroad, combined with a potential recovery in domestic innovative drug R&D demand, are expected to boost CXO companies' performance in the second half of the year [1]. Group 3: Key Companies - Leading companies in the CXO sector include: - Kelaiying (06821) - Kanglong Chemical (03759) - Zhaoyan New Drug (06127) - WuXi Biologics (02269) - WuXi AppTec (02359) [3].

Group 1 - Recent focus on the unlocking of restricted shares in the Hong Kong stock market, with significant declines observed in stock prices, such as a drop of 8.75% for CATL's H-shares [1] - Upcoming unlocks for companies including Sanhua Intelligent Control and Hengrui Medicine, with Hai Tian Flavor Industry scheduled for December, potentially exerting pressure on stock prices [1] - The Hang Seng Technology Index has experienced a correction of over 18% since its peak after the National Day holiday, indicating a broader market trend [1] Group 2 - Continuous inflow of funds into the Hang Seng Technology/ Hong Kong Technology/ Hong Kong Stock Connect Internet sectors, with the Hong Kong Technology ETF (159751) seeing a net inflow of 50.63 million yuan over four days [1] - The average daily net inflow for the Hong Kong Technology ETF reached 12.66 million yuan, highlighting investor interest [1] - Institutional investors are expected to have reduced pressure for profit-taking in November and December, leading to a neutral upward expectation for the index despite economic meeting forecasts [1] Group 3 - The CSI Hong Kong Stock Connect Technology Index (931573) includes top-weighted stocks such as Alibaba, Tencent, and SMIC, with the top ten stocks accounting for 66.81% of the index [2]